Non-opioid analgesic

Nonsteroidal anti-inflammatory drug

CCP: Moderate to severe acute pain

• Hypersensitivity to keTORolac, aspirin, or other NSAIDs
• Active, or history of, peptic ulcer disease
• Recent GI bleeding or perforation
• Asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• Advanced renal disease
• Suspected or confirmed cerebrovascular bleeding
• Concurrent use with aspirin or other NSAIDs
• Labour and delivery
• Preoperative pain prophylaxis

• Onset: 10-30 minutes
• Peak: 1-3 minutes (IV), 30-60 minutes (IM)
• Duration: 4-6 hours

>10%:

• Central nervous system: Headache (17%)
• Gastrointestinal: Gastrointestinal pain (13%), dyspepsia (12%), nausea (12%)

1-10%:

• Cardiovascular: Edema (4%), hypertension
• Central nervous system: Dizziness (7%), drowsiness (6%)
• Dermatologic: Diaphoresis, pruritus, skin rash
• Gastrointestinal: Diarrhea (7%), constipation, flatulence, gastrointestinal fullness, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, heartburn, stomatitis, vomiting
• Hematologic & oncologic: Anemia, prolonged bleeding time, purpura
• Hepatic: Increased liver enzymes
• Local: Pain at injection site (2%)
• Otic: Tinnitus
• Renal: Renal function abnormality

• Inhibits platelet functions.  Contraindicated in patients with cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, and patients at high risk of bleeding.  
• NSAIDs have an increased risk of serious and potentially fatal adverse cardiovascular thrombotic events.
• KeTORolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or intestines. 
• May increase the risk of hyperkalemia, particularly in the elderly, diabetics, patients with renal disease, or concomitant use of other agents that may induce hyperkalemia (e.g., ACE inhibitors).